[HTML][HTML] Therapies beyond Physiological Barriers and Drug Resistance: A Pilot Study and Review of the Literature Investigating If Intrathecal Trastuzumab and New …
OG Trifănescu, D Mitrea, LN Galeș, A Ciornei… - Cancers, 2023 - mdpi.com
Simple Summary Approximately 10% of HER2-positive breast cancer patients will develop
leptomeningeal metastases (LM), characterized by the spread of tumor cells within the …
leptomeningeal metastases (LM), characterized by the spread of tumor cells within the …
2022 年改变晚期乳腺癌临床实践的重要研究
张会强， 江泽飞 - 中国癌症杂志, 2023 - china-oncology.com
随着乳腺癌综合治疗水平的提高和抗肿瘤药物的不断发展, 晚期乳腺癌患者的生存情况有了明显
改善. 乳腺癌进入精细分类, 精确分层的新阶段, 2022 年晚期乳腺癌研究领域取得了多项突破性 …
改善. 乳腺癌进入精细分类, 精确分层的新阶段, 2022 年晚期乳腺癌研究领域取得了多项突破性 …
[HTML][HTML] Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real …
J Huang, S Sun, Q Tan, F Zheng, D Zhou, X Man… - Clinical Breast …, 2024 - Elsevier
Abstract Background Approximately 30% to 50% of patients with human epidermal growth
factor receptor 2-positive metastatic breast cancer develop brain metastasis (BMs). Pyrotinib …
factor receptor 2-positive metastatic breast cancer develop brain metastasis (BMs). Pyrotinib …
Key clinical studies on changing clinical practice of advanced breast cancer in 2022
Z Huiqiang, J Zefei - China Oncology, 2023 - china-oncology.com
With the improvement of comprehensive treatment of breast cancer and the continuous
development of anti-tumor drugs, the survival time of breast cancer patients, especially …
development of anti-tumor drugs, the survival time of breast cancer patients, especially …